Subacute Thyroiditis Clinical Trial
Official title:
Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis
Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute
Thyroiditis
The investigators hypothesize that less adverse reactions will be observed, comparing with
the guidelines recommend. The recurrence rate, adrenal insufficiency, temporary and
permanent hypothyroidism aren't significant difference.
Comparing with the guidelines recommend, short-term (one week)prednisone and nsaids
following up next week to treat moderate and severe subacute thyroiditis will be assessed.
The patients in wards will be assessed from temperature,erythrocyte sedimentation
rate,C-reactive protein,local pain and goiter.The random treatment will be executed in
moderate and severe SAT after informed consent be signed.
Subjects will be monitored once every 2 weeks.If patients complained of pain in their neck
or if the erythrocyte sedimentation rate is still high,after discontinuation of prednisone,
prednisone treatment will be resumed in moderate and severe subject and non-steroidal
anti-inflammatory drugs will be used in mild subject.Anti-ulcer drugs will be administered
to all patients.
The endpoint of the study are efficiency and safety of short-term prednisone treating. The
investigators will assess adrenal insufficiency (such as anorexia, nausea, vomiting,
abdominal pain),steroid withdrawal syndrome, recurrence rate and hypothyroidism. The
investigators will observe erythrocyte sedimentation rate,pain,steroid level and thyroid
function.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06391515 -
Subacute Thyroiditis in the SARS-CoV-2 Era
|
||
| Completed |
NCT05070091 -
The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.
|
||
| Not yet recruiting |
NCT06285617 -
Short-Term Versus 6-Week Prednisone in The Treatment of Subacute Thyroiditis
|
Phase 3 |